title: Improved dose distributions for 3D conformal boost treatments in carcinoma of the nasopharynx.
abstract: This study was designed to demonstrate the feasibility of 3-dimensional (3D) treatment planning in patients with carcinoma of the nasopharynx, and to explore its potential therapeutic advantage over the traditional 2-dimensional (2D) approach in this disease. Qualitative and quantitative comparisons between the two techniques were made for the boost portion of the treatment (19.8 Gy of a total 70.2 Gy treatment schedule) in 10 previously untreated patients and for the entire treatment in 5 patients with locally recurrent disease. The 2D and 3D plans were compared in each patient using dose-volume histograms (DVH's), tumor control probabilities (TCP's), normal tissue complication probabilities (NTCP's), and a new biologic figure of merit that describes the probability of uncomplicated control. Although there was no attempt to optimize the 3D treatment approach by using this method throughout the total treatment course (rather than for the boost only), it was still found that for each of the endpoints examined the 3D approach resulted in improved plans. An average of 22% of the target volume was underdosed at the 95% isodose level with the 2D plans compared to 7% with the 3D plans. The improved treatment planning by 3D increased the mean dose to the tumor volume by an average of 13% over 2D planning. The dose to normal structures such as the mandible and parotid glands was reduced with the 3D plans while the brain stem and spinal cord remained within tolerance limits. The probability of uncomplicated tumor control was increased by an average of 15% with 3D treatment planning compared to the 2D approach. Our findings demonstrate the potential of 3D planning for improving the treatment of carcinoma of the nasopharynx, but prospective studies are required to define the true clinical advantages of this methodology.
authors.affiliation: Dept. of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: S A
authors.initials: SA
authors.lastname: Leibel
authors.forename: G J
authors.initials: GJ
authors.lastname: Kutcher
authors.forename: L B
authors.initials: LB
authors.lastname: Harrison
authors.forename: D E
authors.initials: DE
authors.lastname: Fass
authors.forename: C M
authors.initials: CM
authors.lastname: Burman
authors.forename: M A
authors.initials: MA
authors.lastname: Hunt
authors.forename: R
authors.initials: R
authors.lastname: Mohan
authors.forename: L J
authors.initials: LJ
authors.lastname: Brewster
authors.forename: C C
authors.initials: CC
authors.lastname: Ling
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Fuks
mesh_terms: D006801:Humans; D009303:Nasopharyngeal Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D011336:Probability; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D011879:Radiotherapy Dosage; D014057:Tomography, X-Ray Computed / Q000379:methods